) recently announced positive results from a phase II trial
evaluating the efficacy of its hematology candidate, SAR302503
(selective JAK2 inhibitor) in three dose strengths (300 mg, 400
mg, and 500 mg) for the reduction of spleen volume and
improvement in constitutional symptoms in intermediate-2 or
high-risk primary or secondary myelofibrosis (MF) patients. The
data was presented at the American Society of Hematology's (ASH)
JOHNSON & JOHNS (JNJ): Free Stock Analysis
NOVO-NORDISK AS (NVO): Free Stock Analysis
(RHHBY): ETF Research Reports
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.
The open label, randomized dose-ranging phase II trial evaluated
SAR302503 in 31 patients. The candidate met the primary endpoint
of reducing spleen volume.
Currently, the phase III JAKARTA trial, evaluating the use of
SAR302503 in 289 patients, is underway. Initial data from the
trial should be out by the second quarter of 2013. Two dose
strengths (400 mg and 500 mg) of SAR302503 are being studied in
the JAKARTA trial.
We are pleased with Sanofi's progress with its pipeline. Over the
last few months, several of Sanofi's pipeline candidates gained
approval including US approval of Aubagio (teriflunomide) for
relapsing forms of multiple sclerosis (RMS) and US approval of
Zaltrap (aflibercept) as a combination therapy for
treatment-experienced patients suffering from metastatic
We expect Sanofi to continue to contain operating costs in order
to increase earnings in the face of weakening sales of some of
its biggest products. We also expect the company to pursue
Currently, we have a Neutral recommendation on Sanofi. Sanofi
carries a Zacks #2 Rank (Buy) in the short run.
Large-cap pharma stocks currently holding a Zacks #2 Rank include
Johnson & Johnson